NCT03026556View on ClinicalTrials.gov

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

CompletedOBSERVATIONAL
Enrollment

42,534

Participants

Timeline

Start Date

December 29, 2016

Primary Completion Date

August 23, 2017

Study Completion Date

August 23, 2017

Conditions
Atrial Fibrillation
Interventions
DRUG

Dabigatran vs. Rivaroxaban

observed for 6 years

DRUG

Dabigatran vs. Apixaban

Observed for 6 years

Trial Locations (1)

08450

Inventiv Health, Princeton

Sponsors
All Listed Sponsors
collaborator

Health ResearchTx, LLC (HRTX)

UNKNOWN

collaborator

inVentiv Health Clinical (iVH)

UNKNOWN

collaborator

United States Department of Defense (DOD)

UNKNOWN

lead

Boehringer Ingelheim

INDUSTRY

NCT03026556 - The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis | Biotech Hunter | Biotech Hunter